Galderma
CLICK HERE if you are a Consumer
Roll Over for Important Safety Information

METROGEL® 1%

The One

Topical metronidazole is a frequent choice for the treatment of rosacea. Its efficacy and safety has been reported and confirmed in randomized and controlled clinical trials.

Although the exact mechanism by which metronidazole reduces the inflammatory lesions of rosacea is not fully understood, it is thought that its beneficial effects may result in part from its anti-inflammatory, antimicrobial, and/or anti-oxidant actions.

Because of its water-based gel formulation, METROGEL® (metronidazole) Gel, 1% is capable of solubilizing a higher concentration of metronidazole (1% vs. 0.75%). METROGEL® 1% also offers several advantages including:

  • Niacinamide decreases transepidermal water loss, participates in the solubilizing process of metronidazole
  • Propylene glycol enhances percutaneous delivery
  • Betadex increases skin permeability
  • No damage to the skin barrier following 2 weeks of treatment (N=25)
Suspension formulations such as creams may be less able to penetrate into the skin. Due to its unique gel formulation, METROGEL® 1% has improved cutaneous permeability, and it protects the skin barrier and curbs transepidermal water loss (TEWL).

HELP YOUR PATIENTS
 FIND A DERMATOLOGIST
(Enter the first 3 digits of your zip code)

IMPORTANT SAFETY INFORMATION

METROGEL® (metronidazole) Gel, 1% is a nitroimidazole indicated for the topical treatment of inflammatory lesions of rosacea. The most common adverse reactions that have been reported with the topical use of METROGEL® 1% are nasopharyngitis, upper respiratory tract infections and headaches, as well as dryness, scaling, itching, and stinging. Transient redness, metallic taste, tingling or numbness of extremities and nausea have also been reported with the topical use of metronidazole. METROGEL®1% therapy should be reevaluated if these symptoms occur. Caution should be used when prescribing metronidazole products for patients with blood dyscrasia, and patients using blood thinning agents such as coumarin or warfarin may experience prolonged prothrombin times. METROGEL® 1% is contraindicated in patients with a history of hypersensitivity to metronidazole or any other ingredient in the formulation.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.